Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 12/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1077934 | 0.92 | CYP3A4 (0.64) | CYP3A4CYP2D6GRIN2BFAAHGABRA1 | |
| SCHEMBL1036643 | 0.91 | CYP3A4 (0.62) | CYP3A4CYP2D6GRIN2BFAAHGABRA1 | |
| SCHEMBL1039063 | 0.91 | CYP3A4 (0.62) | CYP3A4CYP2D6GRIN2BFAAHGABRA1 | |
| SCHEMBL1039793 | 0.90 | CYP3A4 (0.60) | CYP3A4CYP2D6GRIN2BFAAHGABRA1 | |
| SCHEMBL1035798 | 0.90 | CYP3A4 (0.62) | CYP3A4CYP2D6GRIN2BFAAHGABRA1 | |
| SCHEMBL1037556 | 0.90 | CYP3A4 (0.62) | CYP3A4CYP2D6GRIN2BFAAHGABRA1 | |
| SCHEMBL1039682 | 0.89 | CYP3A4 (0.61) | CYP3A4CYP2D6FAAHGABRA1ADRA2C | |
| SCHEMBL1038080 | 0.88 | CYP3A4 (0.60) | CYP3A4CYP2D6GRIN2BFAAHGABRA1 | |
| SCHEMBL1039880 | 0.88 | CYP3A4 (0.46) | CYP3A4CYP2D6GRIN2BFAAH | |
| SCHEMBL1039878 | 0.88 | CYP3A4 (0.46) | CYP3A4CYP2D6GRIN2BFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144159-A1 | ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC | 2011-06-16 | — | — | US | disclosed |
| EP-2276735-A1 | ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009127944-A1 | ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC. (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144159-A1 | ETHER BENZYLIDENE PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | FAAH, FAAH2, PAH | CYP3A4 329/4885CYP2D6 382/4885GRIN2B 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.